CN113892031A - 混合检测PCT和Presepsin的试剂盒、方法以及应用 - Google Patents

混合检测PCT和Presepsin的试剂盒、方法以及应用 Download PDF

Info

Publication number
CN113892031A
CN113892031A CN201980096880.8A CN201980096880A CN113892031A CN 113892031 A CN113892031 A CN 113892031A CN 201980096880 A CN201980096880 A CN 201980096880A CN 113892031 A CN113892031 A CN 113892031A
Authority
CN
China
Prior art keywords
soluble
subtype
amino acid
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980096880.8A
Other languages
English (en)
Other versions
CN113892031B (zh
Inventor
于丽娜
李可
何建文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan Panorama Biotechnology Co ltd
Shenzhen Mindray Bio Medical Electronics Co Ltd
Original Assignee
Shenzhen Mindray Bio Medical Electronics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Mindray Bio Medical Electronics Co Ltd filed Critical Shenzhen Mindray Bio Medical Electronics Co Ltd
Priority to CN202211454571.3A priority Critical patent/CN116699141A/zh
Publication of CN113892031A publication Critical patent/CN113892031A/zh
Application granted granted Critical
Publication of CN113892031B publication Critical patent/CN113892031B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

一种混合检测待测样本中的PCT和Presepsin的试剂盒、方法以及应用，该试剂盒包含：捕获抗体混合物，该捕获抗体混合物含有包被在固相上的降钙素原捕获抗体和包被在固相上的可溶性CD14亚型捕获抗体；以及检测抗体混合物，该检测抗体混合物含有经标记的降钙素原检测抗体和经标记的可溶性CD14亚型检测抗体。该试剂盒、方法以及应用能够实现在一个反应体系中检测样本中的PCT和Presepsin的混合信号值，该混合信号值与参考值的比较能够用于评估患者患有脓毒血症的可能性以及评估疑似脓毒血症患者的预后，相比于单独检测样本中的PCT和Presepsin，具有更高的诊断和预后效力。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201980096880.8A 2019-11-19 2019-11-19 混合检测PCT和Presepsin的试剂盒、方法以及应用 Active CN113892031B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211454571.3A CN116699141A (zh) 2019-11-19 2019-11-19 混合检测PCT和Presepsin的试剂盒、方法以及应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/119537 WO2021097685A1 (zh) 2019-11-19 2019-11-19 混合检测PCT和Presepsin的试剂盒、方法以及应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211454571.3A Division CN116699141A (zh) 2019-11-19 2019-11-19 混合检测PCT和Presepsin的试剂盒、方法以及应用

Publications (2)

Publication Number Publication Date
CN113892031A true CN113892031A (zh) 2022-01-04
CN113892031B CN113892031B (zh) 2022-12-09

Family

ID=75979922

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211454571.3A Pending CN116699141A (zh) 2019-11-19 2019-11-19 混合检测PCT和Presepsin的试剂盒、方法以及应用
CN201980096880.8A Active CN113892031B (zh) 2019-11-19 2019-11-19 混合检测PCT和Presepsin的试剂盒、方法以及应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202211454571.3A Pending CN116699141A (zh) 2019-11-19 2019-11-19 混合检测PCT和Presepsin的试剂盒、方法以及应用

Country Status (4)

Country Link
US (1) US20220283182A1 (zh)
EP (1) EP4060338A4 (zh)
CN (2) CN116699141A (zh)
WO (1) WO2021097685A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115407067A (zh) * 2022-06-22 2022-11-29 郑州大学第一附属医院 一种脓毒血症诊断标志物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690890A (en) * 1984-04-04 1987-09-01 Cetus Corporation Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay
CN1711283A (zh) * 2002-11-12 2005-12-21 持田制药株式会社 人低分子量cd14测定试剂盒和抗体
CN101246163A (zh) * 2008-01-29 2008-08-20 广州益善生物技术有限公司 脓毒症早期诊断液相芯片及其制备方法
CN103913579A (zh) * 2014-03-24 2014-07-09 北京普恩光德生物科技开发有限公司 一种降钙素原检测试剂盒
CN208399511U (zh) * 2018-05-29 2019-01-18 江苏扬新生物医药有限公司 一种用于脓毒症快速定量检测的胶体金试剂盒
CN112129952A (zh) * 2020-09-21 2020-12-25 普健生物（武汉）科技有限公司 一种检测人可溶性cd14的化学发光试剂盒
CN113049835A (zh) * 2019-12-27 2021-06-29 深圳市帝迈生物技术有限公司 联合检测试剂盒及检测方法、免疫分析系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1968962B (zh) * 2004-05-11 2013-07-24 持田制药株式会社 新型可溶性cd14抗原
ES2738212T3 (es) * 2011-01-11 2020-01-20 Lsi Medience Corp Procedimiento de predicción de un pronóstico de septicemia
EP2728358B1 (en) * 2011-06-29 2016-10-05 Paichai University Industry-Academic Cooperation Foundation Haptoglobin alpha-r as marker for diagnosing lung cancer
JP5801895B2 (ja) * 2011-08-12 2015-10-28 株式会社Ｌｓｉメディエンス 全身性炎症反応症候群を伴わない術後感染症の検出方法
CN102988956A (zh) * 2011-09-19 2013-03-27 上海人类基因组研究中心 预防、诊断、治疗、预后细菌感染相关疾病的方法和试剂
KR102044940B1 (ko) * 2012-05-07 2019-11-14 가부시키가이샤 엘에스아이 메디엔스 파종성 혈관 내 응고 증후군 또는 감염성 파종성 혈관 내 응고 증후군을 검출하는 방법
CN104777109A (zh) * 2015-03-16 2015-07-15 首都儿科研究所附属儿童医院 一种脓毒症诊断方法及试剂
WO2017160599A1 (en) * 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
WO2018114044A1 (en) * 2016-12-22 2018-06-28 University Of Geneva Biomarker panels for brain injury complications
US20210231683A1 (en) * 2018-04-20 2021-07-29 Unm Rainforest Innovations Rap1-GTP, Rac1-GTP and FMS-like Tyrosine Kinase 3 ligand (FLT3-L) As Biomarkers For Early Detection of Sepsis
CN208060540U (zh) * 2018-04-28 2018-11-06 江苏扬新生物医药有限公司 一种用于脓毒症快速定量检测的多指标胶体金试剂盒
BR112022008068A2 (pt) * 2019-10-28 2022-07-12 Hoffmann La Roche Métodos para auxiliar na avaliação de risco de um paciente com suspeita de sepse e método implementado por computador para a avaliação de um paciente com suspeita de sepse

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690890A (en) * 1984-04-04 1987-09-01 Cetus Corporation Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay
CN1711283A (zh) * 2002-11-12 2005-12-21 持田制药株式会社 人低分子量cd14测定试剂盒和抗体
CN101246163A (zh) * 2008-01-29 2008-08-20 广州益善生物技术有限公司 脓毒症早期诊断液相芯片及其制备方法
CN103913579A (zh) * 2014-03-24 2014-07-09 北京普恩光德生物科技开发有限公司 一种降钙素原检测试剂盒
CN208399511U (zh) * 2018-05-29 2019-01-18 江苏扬新生物医药有限公司 一种用于脓毒症快速定量检测的胶体金试剂盒
CN113049835A (zh) * 2019-12-27 2021-06-29 深圳市帝迈生物技术有限公司 联合检测试剂盒及检测方法、免疫分析系统
CN112129952A (zh) * 2020-09-21 2020-12-25 普健生物（武汉）科技有限公司 一种检测人可溶性cd14的化学发光试剂盒

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FAHMY T. ALI ET AL: "Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis", 《CLINICA CHIMICA ACTA》 *
NAGWAN I.RASHWAN ET AL: "Validity of Biomarkers in Screening for Neonatal Sepsis-A Single-Center Hospital- based Study", 《PREDIATRICS AND NEONATOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115407067A (zh) * 2022-06-22 2022-11-29 郑州大学第一附属医院 一种脓毒血症诊断标志物

Also Published As

Publication number Publication date
CN113892031B (zh) 2022-12-09
CN116699141A (zh) 2023-09-05
US20220283182A1 (en) 2022-09-08
WO2021097685A1 (zh) 2021-05-27
EP4060338A1 (en) 2022-09-21
EP4060338A4 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
US8124722B2 (en) Soluble CD14 antigen
US7087396B2 (en) Monoclonal antibody and method and kit for immunoassay of soluble human ST2
RU2753512C2 (ru) Антитело против злокачественной клетки, противораковое лекарственное средство и способ тестирования злокачественного новообразования
CA2481710A1 (en) Method of judging leukemia, pre-leukemia or aleukemic malignant blood disease and diagnostic therefor
US10494430B2 (en) Anti-active GIP antibody
US20140243265A1 (en) Antibodies to modified human igf-1/e peptides
KR102360851B1 (ko) 신규 항프레세프신 항체
JP5437633B2 (ja) モノクローナル抗体およびその用途
KR20120064072A (ko) 콜라겐 네오에피토프 항체
CN113892031B (zh) 混合检测PCT和Presepsin的试剂盒、方法以及应用
CN113939314B (zh) 新的抗可溶性cd14亚型抗体及其应用
US10421812B2 (en) Isoform specific soluble FMS-like tyrosine kinase (sFlt) binding agents and uses thereof
CN113939533B (zh) 抗可溶性cd14亚型抗体、试剂盒及其应用
CN111303289B (zh) 抗人Tn型糖基化MUC1抗体及其用途
EP1213302B1 (en) Specific antibody directed to active but not inactive hepatocyte growth factor activator (HGFA)
RU2530553C2 (ru) Рекомбинантное однодоменное антитело, способное специфически связывать фактор некроза опухолей человека, и его производные
JP7366411B2 (ja) ヒトαディフェンシンＨＤ５を検出する方法及びキット、並びにこれらにおいて用いられる抗体
JP2002356500A (ja) 活性型肝細胞増殖因子アクティベーターに対する特異的抗体とその使用法
TW202323286A (zh) 抗EphA4抗體
WO2012113718A1 (en) A diagnostic method for type ii diabetes
JP2011160696A (ja) 修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体
JP2019210211A (ja) ウシプロカルシトニンを特異的に認識する抗体、その抗原結合断片、および、その使用
JP2005314397A (ja) 抗コンドロモジュリン−１特異的抗体及びその利用
JP2003274946A (ja) 肝細胞増殖因子活性化因子阻害因子−１に対する抗体とその用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220324

Address after: 430223 workshop (part) on the third floor of Building 1, zone B, Wuhan high tech medical device Park, No. 818, Gaoxin Avenue, Wuhan East Lake New Technology Development Zone, Wuhan, Hubei Province (Wuhan area of free trade zone)

Applicant after: Wuhan panorama Biotechnology Co.,Ltd.

Applicant after: SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS Co.,Ltd.

Address before: 518057 MINDRAY building, 12 South tech Road, Nanshan District hi tech Industrial Park, Shenzhen, Guangdong

Applicant before: SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS Co.,Ltd.

GR01 Patent grant
GR01 Patent grant